Literature DB >> 12455087

Closure of secundum atrial septal defects with the Amplatzer septal occluder device: techniques and problems.

Richard W Harper1, Philip M Mottram, David J McGaw.   

Abstract

Percutaneous transvenous closure of atrial septal defects (ASDs) has become feasible in recent years, as later-generation devices have largely overcome initial difficulties in device deployment and complication rates. The Amplatzer septal occluder (ASO) is one such device that we have used extensively and is, in our opinion, the most versatile and practical to use. It is capable of closing defects up to 40 mm in diameter via a relatively low-profile delivery sheath. More importantly, the ASO may be easily withdrawn into the sheath after deployment but prior to release, which is essential in safely closing difficult defects where successful positioning on the initial deployment is not guaranteed. In this article based on our experience, review of the literature, and communications with other operators, we describe the various problems encountered in closing atrial septal defects and make suggestions as to the best way of overcoming these difficulties. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12455087     DOI: 10.1002/ccd.10353

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  23 in total

Review 1.  Closing down: transcatheter closure of intracardiac defects and vessel embolisations.

Authors:  Jean-François Piéchaud
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

Review 2.  Atrial septum defect closure device in a beating heart, from the perspective of a researcher in artificial organs.

Authors:  Yasuko Tomizawa
Journal:  J Artif Organs       Date:  2012-06-23       Impact factor: 1.731

3.  Comparison of Figulla Flex® and Amplatzer™ devices for atrial septal defect closure: A meta-analysis.

Authors:  Alvaro Aparisi; Roman J Arnold; Hipólito Gutiérrez; Ana Revilla; Ana Serrador; Benigno Ramos; Tania Rodriguez-Gabella; Alberto Campo; Carlos Baladrón; Itziar Gómez; Manuel Carrasco-Moraleja; José A San Roman; Ignacio J Amat-Santos
Journal:  Cardiol J       Date:  2020-04-24       Impact factor: 2.737

4.  Auto-reactive myocarditis after percutaneous closure of an atrial septal defect.

Authors:  Cristina Chimenti; Marco Agrusta; Angelo Cioppa; Ester Campopiano; Paolo Rubino; Andrea Frustaci
Journal:  Intensive Care Med       Date:  2008-07-04       Impact factor: 17.440

5.  Transthoracic echocardiography is a safe alternative for assessment and guidance of transcatheter closure of secundum atrial septal defect in children.

Authors:  Alban-Elouen Baruteau; Sébastien Hascoët; Alain Fraisse
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

6.  Comparison of the Occlutech ® Figulla ® septal occluder and Amplatzer ® septal occluder for atrial septal defect device closure.

Authors:  Supaporn Roymanee; Worakan Promphan; Nakharin Tonklang; Kanjarut Wongwaitaweewong
Journal:  Pediatr Cardiol       Date:  2015-01-30       Impact factor: 1.655

7.  Cor triatriatum dexter and atrial septal defect in a 43-year-old woman.

Authors:  Petar M Vukovic; Dragana Kosevic; Miroslav Milicic; Ljiljana Jovovic; Ivan Stojanovic; Slobodan Micovic
Journal:  Tex Heart Inst J       Date:  2014-08-01

Review 8.  Antiplatelet therapy in valvular and structural heart disease interventions.

Authors:  Annunziata Nusca; Edoardo Bressi; Iginio Colaiori; Marco Miglionico; Germano Di Sciascio
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

Review 9.  Challenges encountered during closure of atrial septal defects.

Authors:  W Knirsch; A Dodge-Khatami; E Valsangiacomo-Buechel; M Weiss; F Berger
Journal:  Pediatr Cardiol       Date:  2005 Mar-Apr       Impact factor: 1.655

10.  Transthoracic echocardiography guidance of transcatheter atrial septal defect closure in children.

Authors:  Mahmoud Zaqout; Bert Suys; Hans De Wilde; Daniel De Wolf
Journal:  Pediatr Cardiol       Date:  2009-05-21       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.